Advisor Group Holdings, Inc. Athenex, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.12 - $0.21 $3,240 - $5,670	-27,000 Reduced 68.94%	12,163 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $1.11 $480 - $2,220	2,000 Added 5.38%	39,163 $10,000
Q2 2022 Aug 10, 2022	BUY	$0.41 - $0.91 $820 - $1,820	2,000 Added 5.69%	37,163 $16,000
Q1 2022 May 04, 2022	BUY	$0.79 - $1.59 $5,214 - $10,494	6,600 Added 23.11%	35,163 $29,000
Q3 2021 Nov 05, 2021	BUY	$2.97 - $4.84 $33,828 - $55,127	11,390 Added 66.33%	28,563 $87,000
Q2 2021 Aug 02, 2021	SELL	$3.71 - $5.13 $180,714 - $249,882	-48,710 Reduced 73.93%	17,173 $80,000
Q1 2021 May 13, 2021	BUY	$4.08 - $14.75 $230,193 - $832,195	56,420 Added 596.22%	65,883 $283,000
Q4 2020 Feb 10, 2021	BUY	$11.06 - $14.01 $18,802 - $23,817	1,700 Added 21.9%	9,463 $104,000
Q3 2020 Nov 12, 2020	BUY	$10.26 - $14.55 $37,582 - $53,296	3,663 Added 89.34%	7,763 $93,000
Q1 2020 May 18, 2020	BUY	$5.71 - $15.85 $23,411 - $64,985	4,100 New	4,100 $32,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.